Form 4: Repligen CEO Olivier Loeillot Reports Stock and Option Awards

CEO Olivier Loeillot reports the acquisition of restricted stock units and stock options in Repligen Corporation.

Summary

• On September 3, 2024, Olivier Loeillot, CEO of Repligen Corporation, reported the acquisition of 17,631 restricted stock units and 16,278 stock options.
• The restricted stock units vest in equal annual installments over three years, beginning on the first anniversary of the grant date and can only be settled in shares of Repligen's common stock.
• One third of the stock options will vest annually on September 3, 2025, September 3, 2026, and September 3, 2027.
• Following these transactions, Loeillot directly owns 33,417 shares of Repligen's common stock and 16,278 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

• The grant of restricted stock units and stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock and option awards are a common practice in the biotech industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Danaher and Thermo Fisher Scientific also utilize stock options and restricted stock units as part of their executive compensation plans.

Stakeholder Impact

• The stock and option awards incentivize the CEO to improve company performance, which benefits shareholders.
• The awards do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates